A real‐life experience of long‐term use of pilocarpine in irradiated head and neck cancer patients
Oral Diseases · 2024
DOI: 10.1111/odi.14905 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Oral Diseases, 2024. Verfasst von Rungarun Kittichet und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Prince of Songkhla University, Songkhla, Thailand. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Pilocarpine, Xerostomia, Radiation Injuries. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Aims
To assess long‐term efficacy and side effects of pilocarpine on irradiated head and neck cancer (HNC) patients in both for prevention and treatment of radiation‐induced xerostomia (RIX).
Methods
Retrospective observational study was conducted. Eligibility criteria included irradiated HNC patients who received pilocarpine at least 12 weeks either for prevention (group A) or for treatment (group B) of RIX. We collected the documented Late Effect Normal Tissue Task Force‐Subjective, Objective, Management, Analytics subjective/objective grades of RIX before (only group B) and the latest visit for pilocarpine prescription, dosage, side effects, duration of treatment, and the cause of discontinuation.
Results
Between December 2007 and June 2022, 182 patients were enrolled including 95 patients (52%) in group A and 87 patients (48%) in group B. Group A patients reported grades 1, 2, 3, and 4 objective RIX in 0%, 7%, 93%, and 0%. Grade 1, 2, and 3 subjective RIX were 57%, 28%, and 15%. All patients in group B had grade 3 both objective/subjective RIX. The overall improvement of objective/subjective RIX was found in 40%/83%. Discontinuation was found in 51% of patients due to tolerable symptoms or deterioration of the patient's status.
Conclusions
Based on this retrospective analysis, long‐term use of pilocarpine in irradiated HNC appears feasible for both prevention and treatment of RIX.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Prince of Songkhla University, Songkhla, Thailand.
- Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
- Northern Thai Research Group of Radiation Oncology (NTRG-RO), Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
- Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
ORCID-Profile: Imjai Chitapanarux
Zitieren
APA
Kittichet, R., Chitapanarux, I., Kittidachanan, K., & Sripan, P. (2024). A real‐life experience of long‐term use of pilocarpine in irradiated head and neck cancer patients. Oral Diseases. https://doi.org/10.1111/odi.14905
Vancouver
Kittichet R, Chitapanarux I, Kittidachanan K, Sripan P. A real‐life experience of long‐term use of pilocarpine in irradiated head and neck cancer patients. Oral Diseases. 2024. doi:10.1111/odi.14905
BibTeX
@article{Kittichet2024,
author = {Kittichet, Rungarun and Chitapanarux, Imjai and Kittidachanan, Kittikun and Sripan, Patumrat},
title = {A real‐life experience of long‐term use of pilocarpine in irradiated head and neck cancer patients},
journal = {Oral Diseases},
year = {2024},
doi = {10.1111/odi.14905}
}
EUVIMED